I would give them an "F" on communications. I'm sure Don has a tremendous workload on his plate being CEO of both companies but that does not excuse him from doing basic communications such as how the FDA prostate cancer trial is going.

He could also provide us with some sort of update regarding the reverse take over strategy to get the TSX and/or NASDAQ listing(s). It concerns me that he promised a Q4 2015 IPO and failed to deliver. But, in hind sight, based to the last update it appears that Zenith is not far along enough to be able to present significant value of the Zenith compounds and hence an IPO would go out at a very low share price... and yet it wood provide liquidity for those that want out now.

I do believe that the restructuring to Zenith Capital and Zenith Epigenetics also involves a bit of chess related to a public listing. Would a listing be just for the umbrella company? Would IPO's be structured around compounds...each with the opportunity to spin out over a period of years as the testing moves through different stages and trial phases?

Anyway, we do know it is about the science and if it delivers it will completely change the chess game and Don knows it. If the castration resistant metastatic prostate cancer trial shows early positive results it will make it more viable to spin out zen3694 in an IPO and keep the royalty side and epigenetic platform private for more spin offs as they develop the 1500 compounds.

I'm sure there is a tremendous amount of activity on all fronts being done by this company...as frustrated as I am.

Just thinking out loud here.

Toinv